Zheng Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zheng Xue has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Nigar Nargis
American Cancer Society, Atlanta, Georgia, USA
14 shared publications - Samuel Asare
American Cancer Society
12 shared publications - Johann Lee Westmaas
Tobacco Control Research, Department of Surveillance, Prevention, and Health Services Research, American Cancer Society, Atlanta, Georgia
8 shared publications - Minal Patel
Tobacco Control Research, Surveillance, Prevention, and Health Services Research, American Cancer Society, Atlanta, Georgia
8 shared publications - Priti Bandi
Surveillance & Health Equity Science, American Cancer Society , Atlanta, GA
7 shared publications - Ahmedin Jemal
Surveillance, Prevention, and Health Services Research American Cancer Society Atlanta Georgia USA
4 shared publications
Latest Publications
- Open Access
Electronic nicotine delivery systems versus nicotine replacement therapies and risk of smoking relapse: evidence from a US nationwide prospective cohort (Cancer Prevention Study-3)
Objective To compare use of electronic nicotine delivery systems (ENDS) with nicotine replacement therapies (NRTs) on risk of cigarette smoking relapse by people who had already quit cigarettes. Design Prospective cohort study. Setting The American Cancer Society Cancer Prevention Study-3, a nationwide US cohort with follow-up every 3 years beginning in 2015. Participants Adults who in 2015 had already quit smoking (n=3112) or were smoking (n=1018) and who in 2018 reported past or current exclusive use of ENDS or NRT and provided smoking status. Outcome measures Relapse to cigarette smoking in 2018 among people who were already quit in 2015, and abstinence from cigarettes in 2018 among people who were smoking in 2015. Results Among respondents who had already quit in 2015, the unadjusted risk of relapse in 2018 was approximately three times greater for those who reported past exclusive ENDS versus past exclusive NRT use (11.2% vs 3.9%; relative risk (RR)=2.90, 95% CI 2.12 to 3.98). This association remained significant in a multivariable-adjusted model (RR=2.09, 95% CI 1.49 to 2.92). Among those smoking in 2015, the unadjusted likelihood of abstinence in 2018 was higher for those who reported current ENDS versus NRT use (RR=1.35, 95% CI 1.01 to 1.80), but the multivariable model adjusted for smoking frequency indicated no difference in abstinence (RR=1.38; 95% CI 0.93 to 2.05). Conclusions ENDS use was associated with greater relapse risk than NRT among people who had already quit. Although ENDS may support shorter-term cessation, further long-term observational research is needed to clarify relapse risks associated with ENDS relative to NRT.
Open AccessElectronic nicotine delivery systems versus nicotine replacement therapies and risk of smoking relapse: evidence from a US nationwide prospective cohort (Cancer Prevention Study-3)
Objective To compare use of electronic nicotine delivery systems (ENDS) with nicotine replacement therapies (NRTs) on risk of cigarette smoking relapse by people who had already quit cigarettes. Design Prospective cohort study. Setting The American Cancer Society Cancer Prevention Study-3, a nationwide US cohort with follow-up every 3 years beginning in 2015. Participants Adults who in 2015 had already quit smoking (n=3112) or were smoking (n=1018) and who in 2018 reported past or current exclusive use of ENDS or NRT and provided smoking status. Outcome measures Relapse to cigarette smoking in 2018 among people who were already quit in 2015, and abstinence from cigarettes in 2018 among people who were smoking in 2015. Results Among respondents who had already quit in 2015, the unadjusted risk of relapse in 2018 was approximately three times greater for those who reported past exclusive ENDS versus past exclusive NRT use (11.2% vs 3.9%; relative risk (RR)=2.90, 95% CI 2.12 to 3.98). This association remained significant in a multivariable-adjusted model (RR=2.09, 95% CI 1.49 to 2.92). Among those smoking in 2015, the unadjusted likelihood of abstinence in 2018 was higher for those who reported current ENDS versus NRT use (RR=1.35, 95% CI 1.01 to 1.80), but the multivariable model adjusted for smoking frequency indicated no difference in abstinence (RR=1.38; 95% CI 0.93 to 2.05). Conclusions ENDS use was associated with greater relapse risk than NRT among people who had already quit. Although ENDS may support shorter-term cessation, further long-term observational research is needed to clarify relapse risks associated with ENDS relative to NRT.
- Open Access
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108114
Prevalence, Patterns, and Correlates of Cannabis–Cigarette Co-Use: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023–2024
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108114
Open AccessPrevalence, Patterns, and Correlates of Cannabis–Cigarette Co-Use: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023–2024
- Open Access
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108117
Tobacco Use Among Individuals With Medical Conditions: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023–2024
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108117
Open AccessTobacco Use Among Individuals With Medical Conditions: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023–2024
- Open Access
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108060
Understanding the Sources of Subnational Disparities in Cigarette Smoking Prevalence: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023–2024
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108060
Open AccessUnderstanding the Sources of Subnational Disparities in Cigarette Smoking Prevalence: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023–2024
- Open Access
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108118
Intended Behaviors in Anticipation of a National Menthol Flavor Ban: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023–2024
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108118
Open AccessIntended Behaviors in Anticipation of a National Menthol Flavor Ban: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023–2024
- Open Access
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108059
Dual Use of Combustible and Electronic Cigarettes: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023
- 27 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (2) , 108059
Open AccessDual Use of Combustible and Electronic Cigarettes: Findings From a Multi-State Rapid-Response Survey in the U.S., 2023
- Open Access
- 15 April 2025
- Published by BMJ in Tobacco Control
- Vol. 35 (4) , 528-533
Electronic cigarette use, related health outcomes and policy interventions in the USA: a call for research to fill evidence gaps
The population-level health consequences of electronic cigarette (e-cigarette) use are heavily debated. This special communication provides updated evidence and identifies knowledge gaps across domains including: (1) health-related outcomes associated with e-cigarette use; (2) initiation and use of e-cigarettes among youth and young adults; (3) concurrent use of electronic and combustible cigarettes; (4) transitions from combustible cigarette use to exclusive e-cigarette use among adults who currently smoke cigarettes and (5) existing e-cigarette-related policy interventions. Literature was searched through PubMed and Medline for systematic reviews, scoping reviews, meta-analyses and primary research articles including emerging topics not covered in reviews published between 1 January 2017 and 1 January 2024. E-cigarette use is associated with several adverse acute health outcomes; there is currently insufficient longitudinal evidence to predict chronic health outcomes. Prevalence of e-cigarette use among youth is considerable and may be associated with subsequent combustible cigarette smoking. Evidence for the health and behavioural impact of dual use of e-cigarettes and combustible cigarettes is limited by imprecise measurement of exposure. Evidence on adults completely substituting combustible cigarettes for e-cigarettes is strong in clinical trials; observational studies do not show complete substitution. Finally, the effects of e-cigarette-related policy interventions to restrict e-cigarette consumption are currently limited in scope and too short-lived to draw causal inferences. Substantial evidence gaps related to the use, associated health impacts and regulation of e-cigarettes in the USA are identified, and we suggest key areas for future research to address that are crucial for informing the public health approach to e-cigarettes.
- 15 April 2025
- Published by BMJ in Tobacco Control
- Vol. 35 (4) , 528-533
Open AccessElectronic cigarette use, related health outcomes and policy interventions in the USA: a call for research to fill evidence gaps
The population-level health consequences of electronic cigarette (e-cigarette) use are heavily debated. This special communication provides updated evidence and identifies knowledge gaps across domains including: (1) health-related outcomes associated with e-cigarette use; (2) initiation and use of e-cigarettes among youth and young adults; (3) concurrent use of electronic and combustible cigarettes; (4) transitions from combustible cigarette use to exclusive e-cigarette use among adults who currently smoke cigarettes and (5) existing e-cigarette-related policy interventions. Literature was searched through PubMed and Medline for systematic reviews, scoping reviews, meta-analyses and primary research articles including emerging topics not covered in reviews published between 1 January 2017 and 1 January 2024. E-cigarette use is associated with several adverse acute health outcomes; there is currently insufficient longitudinal evidence to predict chronic health outcomes. Prevalence of e-cigarette use among youth is considerable and may be associated with subsequent combustible cigarette smoking. Evidence for the health and behavioural impact of dual use of e-cigarettes and combustible cigarettes is limited by imprecise measurement of exposure. Evidence on adults completely substituting combustible cigarettes for e-cigarettes is strong in clinical trials; observational studies do not show complete substitution. Finally, the effects of e-cigarette-related policy interventions to restrict e-cigarette consumption are currently limited in scope and too short-lived to draw causal inferences. Substantial evidence gaps related to the use, associated health impacts and regulation of e-cigarettes in the USA are identified, and we suggest key areas for future research to address that are crucial for informing the public health approach to e-cigarettes.
- Open Access
- 15 April 2025
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27 (9) , 1591-1599
Nicotine and Toxicant Exposure among Individuals using both Combustible Cigarettes and E-cigarettes Based on Level of Product Use
Introduction: Dual use of combustible cigarettes and e-cigarettes is the most common multiple tobacco-use behavior in the United States, but its long-term health impact remains unclear. Biomarkers of exposure (BOE) can help identify potential health risks of dual use. Methods: We analyzed data from 2,679 adult participants from Wave 5 of the Population Assessment on Tobacco and Health Study, a U.S. nationally representative study, including individuals reporting current exclusive cigarette use (n = 1,913), exclusive e-cigarette use (n = 316), and dual use (n = 450). Eight subgroups were created based on self-reported high/low (above/below mean) cigarettes per day (CPD) and days of e-cigarette use in past the 30 days (ECIG). Adjusted geometric mean concentrations were compared for total nicotine equivalents, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), three volatile organic compounds (VOCs), and heavy metals (lead and cadmium). Results: Individuals reporting dual use did not differ from those reporting exclusive cigarette use on CPD (13.1 vs. 11.8, respectively). Dual-use groups with high CPD had higher levels of NNAL and VOCs compared to those with low CPD (eg, NNAL for high CPD/high ECIG: 257.07 ng/mg creatinine vs. low CPD/high ECIG: 64.57 ng/mg creatinine, p < .001; high CPD/low ECIG: 312.02 ng/mg creatinine vs. low CPD/low ECIG: 144.11 ng/mg creatinine, p < .001). Cigarette use (dual or exclusive use) was generally associated with higher BOE than exclusive e-cigarette use, though metal exposure did not differ between groups. Conclusions: Dual use and exclusive cigarette use are associated with higher toxicant exposure compared to exclusive e-cigarette use. Implications: In this population-based cross-sectional study, individuals reporting dual use appear to have nicotine and toxicant exposure at least at the same level as those using cigarettes alone and higher than exclusive e-cigarette use (except for metals). Given the adverse health consequences of dual use, including potential cancer risk, our findings highlight the need for clinicians and public health practitioners to increase awareness of the potential risks associated with dual use.
- 15 April 2025
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27 (9) , 1591-1599
Open AccessNicotine and Toxicant Exposure among Individuals using both Combustible Cigarettes and E-cigarettes Based on Level of Product Use
Introduction: Dual use of combustible cigarettes and e-cigarettes is the most common multiple tobacco-use behavior in the United States, but its long-term health impact remains unclear. Biomarkers of exposure (BOE) can help identify potential health risks of dual use. Methods: We analyzed data from 2,679 adult participants from Wave 5 of the Population Assessment on Tobacco and Health Study, a U.S. nationally representative study, including individuals reporting current exclusive cigarette use (n = 1,913), exclusive e-cigarette use (n = 316), and dual use (n = 450). Eight subgroups were created based on self-reported high/low (above/below mean) cigarettes per day (CPD) and days of e-cigarette use in past the 30 days (ECIG). Adjusted geometric mean concentrations were compared for total nicotine equivalents, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), three volatile organic compounds (VOCs), and heavy metals (lead and cadmium). Results: Individuals reporting dual use did not differ from those reporting exclusive cigarette use on CPD (13.1 vs. 11.8, respectively). Dual-use groups with high CPD had higher levels of NNAL and VOCs compared to those with low CPD (eg, NNAL for high CPD/high ECIG: 257.07 ng/mg creatinine vs. low CPD/high ECIG: 64.57 ng/mg creatinine, p < .001; high CPD/low ECIG: 312.02 ng/mg creatinine vs. low CPD/low ECIG: 144.11 ng/mg creatinine, p < .001). Cigarette use (dual or exclusive use) was generally associated with higher BOE than exclusive e-cigarette use, though metal exposure did not differ between groups. Conclusions: Dual use and exclusive cigarette use are associated with higher toxicant exposure compared to exclusive e-cigarette use. Implications: In this population-based cross-sectional study, individuals reporting dual use appear to have nicotine and toxicant exposure at least at the same level as those using cigarettes alone and higher than exclusive e-cigarette use (except for metals). Given the adverse health consequences of dual use, including potential cancer risk, our findings highlight the need for clinicians and public health practitioners to increase awareness of the potential risks associated with dual use.
- 13 February 2025
- Published by BMJ in Tobacco Control
- Vol. 35 (3) , 366-374
Association of menthol-flavoured cigarette smoking with all-cause and cause-specific mortality risk
Introduction: Menthol-flavoured cigarettes remain unregulated in the USA and in many low- and middle-income countries (LMICs) despite their known impacts on smoking uptake and reduced cessation. Yet, evidence about whether menthol cigarettes are associated with higher disease risks than non-menthol cigarettes is inconclusive, and the industry has used this argument to lobby against regulation. Methods: All-cause and cause-specific mortality risk was assessed according to baseline smoking status (current, former and never) and menthol flavour status (menthol and non-menthol) of the cigarette brand smoked for the longest period among 969 349 persons from Cancer Prevention Study-II, a population-based prospective cohort study enrolled in 19821983 with mortality follow-up of 6 years. Results: 73 486 and 281 680 persons reported menthol brands and non-menthol brands, respectively, among whom 4071 and 20 738 deaths occurred, respectively. Currently smoking cigarettes, whether menthol or non-menthol brands, was associated with highest mortality risks (eg, all causes: about two times higher risk vs never smoking) but quitting substantially reduced risks for both types. Among persons who formerly smoked, menthol versus non-menthol smoking was associated with an elevated mortality risk of 12% from all-causes, 16% from all cardiovascular diseases, 13% from ischaemic heart disease, and 43% from other heart diseases Among individuals currently smoking, there was no difference in mortality risks for menthol versus non-menthol cigarettes except for elevated risk among those smoking=40 cigarettes per day. Black persons currently smoking menthol versus non-menthol brands had an 88% elevated mortality risk for other heart diseases. Conclusion: Findings of a unique excess mortality risk associated with menthol cigarettes provide additional scientific evidenceapart from their known impacts on initiation and cessationin support of menthol flavour regulation in the USA and similar policies in LMICs. Public communication efforts must reiterate that quitting all cigarette types is the only safe option to reduce disease risk.
- 13 February 2025
- Published by BMJ in Tobacco Control
- Vol. 35 (3) , 366-374
Association of menthol-flavoured cigarette smoking with all-cause and cause-specific mortality risk
Introduction: Menthol-flavoured cigarettes remain unregulated in the USA and in many low- and middle-income countries (LMICs) despite their known impacts on smoking uptake and reduced cessation. Yet, evidence about whether menthol cigarettes are associated with higher disease risks than non-menthol cigarettes is inconclusive, and the industry has used this argument to lobby against regulation. Methods: All-cause and cause-specific mortality risk was assessed according to baseline smoking status (current, former and never) and menthol flavour status (menthol and non-menthol) of the cigarette brand smoked for the longest period among 969 349 persons from Cancer Prevention Study-II, a population-based prospective cohort study enrolled in 19821983 with mortality follow-up of 6 years. Results: 73 486 and 281 680 persons reported menthol brands and non-menthol brands, respectively, among whom 4071 and 20 738 deaths occurred, respectively. Currently smoking cigarettes, whether menthol or non-menthol brands, was associated with highest mortality risks (eg, all causes: about two times higher risk vs never smoking) but quitting substantially reduced risks for both types. Among persons who formerly smoked, menthol versus non-menthol smoking was associated with an elevated mortality risk of 12% from all-causes, 16% from all cardiovascular diseases, 13% from ischaemic heart disease, and 43% from other heart diseases Among individuals currently smoking, there was no difference in mortality risks for menthol versus non-menthol cigarettes except for elevated risk among those smoking=40 cigarettes per day. Black persons currently smoking menthol versus non-menthol brands had an 88% elevated mortality risk for other heart diseases. Conclusion: Findings of a unique excess mortality risk associated with menthol cigarettes provide additional scientific evidenceapart from their known impacts on initiation and cessationin support of menthol flavour regulation in the USA and similar policies in LMICs. Public communication efforts must reiterate that quitting all cigarette types is the only safe option to reduce disease risk.
- 24 July 2023
- Published by BMJ in Tobacco Control
- Vol. 34 (1) , 41-47
Association between cigarette sales in the USA and FDA’s announcement of its intention to prohibit menthol as a characterising flavour in cigarettes
Introduction On 29 April 2021, the US Food and Drug Administration (FDA) announced its intention to prohibit menthol as a characterising flavour in cigarettes. Methods We assessed the changes in cigarette sales associated with the FDA’s announcement using interrupted time series analysis based on monthly retail point-of-sale data on cigarettes from the NielsenIQ Local Trade Area (LTA) data from September 2019 to April 2022. Main outcome variables included LTA-level monthly menthol and non-menthol cigarette sales per 1000-persons. Results Monthly cigarette sales were declining before the FDA’s announcement (menthol vs non-menthol: −1.68 (95% CI −1.92, −1.45) vs −3.14 (95% CI −3.33, −2.96) packs per 1000-persons). Monthly menthol cigarette sales increased immediately in May 2021 after the FDA’s announcement by 6.44 packs per 1000-persons (95% CI 3.83, 9.05). Analysis stratified by LTA-level racial/ethnic compositions showed that LTAs with a relatively higher proportion of non-Hispanic Black population (>8.94%) experienced higher spike in menthol cigarette sales in May 2021 immediately after the announcement and higher post-announcement 12-month menthol cigarette sales than expected. Conclusions Areas with a relatively higher proportion of non-Hispanic Black population are potentially at risk of experiencing increased burden of menthol cigarette consumption. Targeted community level cessation support in non-Hispanic Black majority areas may help mitigate the growing burden of menthol cigarette smoking and improve health equity. The findings of this study also suggest that FDA’s prompt finalisation and enforcement of such ban may help avoid extending the increased burden of menthol cigarette consumptions in non-Hispanic Black majority areas.
- 24 July 2023
- Published by BMJ in Tobacco Control
- Vol. 34 (1) , 41-47
Association between cigarette sales in the USA and FDA’s announcement of its intention to prohibit menthol as a characterising flavour in cigarettes
Introduction On 29 April 2021, the US Food and Drug Administration (FDA) announced its intention to prohibit menthol as a characterising flavour in cigarettes. Methods We assessed the changes in cigarette sales associated with the FDA’s announcement using interrupted time series analysis based on monthly retail point-of-sale data on cigarettes from the NielsenIQ Local Trade Area (LTA) data from September 2019 to April 2022. Main outcome variables included LTA-level monthly menthol and non-menthol cigarette sales per 1000-persons. Results Monthly cigarette sales were declining before the FDA’s announcement (menthol vs non-menthol: −1.68 (95% CI −1.92, −1.45) vs −3.14 (95% CI −3.33, −2.96) packs per 1000-persons). Monthly menthol cigarette sales increased immediately in May 2021 after the FDA’s announcement by 6.44 packs per 1000-persons (95% CI 3.83, 9.05). Analysis stratified by LTA-level racial/ethnic compositions showed that LTAs with a relatively higher proportion of non-Hispanic Black population (>8.94%) experienced higher spike in menthol cigarette sales in May 2021 immediately after the announcement and higher post-announcement 12-month menthol cigarette sales than expected. Conclusions Areas with a relatively higher proportion of non-Hispanic Black population are potentially at risk of experiencing increased burden of menthol cigarette consumption. Targeted community level cessation support in non-Hispanic Black majority areas may help mitigate the growing burden of menthol cigarette smoking and improve health equity. The findings of this study also suggest that FDA’s prompt finalisation and enforcement of such ban may help avoid extending the increased burden of menthol cigarette consumptions in non-Hispanic Black majority areas.